

Title (en)

TREATMENT OF CROHN'S DISEASE OR PSORIASIS USING ANTI-INTEFERON GAMMA ANTIBODIES

Title (de)

BEHANDLUNG VON MORBUS CROHN ODER PSORIASIS MIT ANTI-INTEFERON GAMMA ANTİKÖRPERN

Title (fr)

TRAITEMENT DE LA MALADIE DE CROHN OU DU PSORIASIS A PARTIR D'ANTICORPS ANTI-INTERFERON GAMMA

Publication

EP 1506002 A4 20060607 (EN)

Application

EP 03753102 A 20030516

Priority

- US 0315874 W 20030516
- US 15074202 A 20020517
- US 38331002 P 20020522

Abstract (en)

[origin: WO03097082A2] The present invention provides a method of treating autoimmune diseases. In particular, it provides a method for the treatment of Crohn's disease or psoriasis comprising administering to a subject in need thereof a therapeutically effective amount of an antibody against interferon gamma.

IPC 8 full level

A61K 38/21 (2006.01); **A61K 39/395** (2006.01); **A61P 1/00** (2006.01); **A61P 1/04** (2006.01); **A61P 1/16** (2006.01); **A61P 3/10** (2006.01); **A61P 5/14** (2006.01); **A61P 7/06** (2006.01); **A61P 13/12** (2006.01); **A61P 17/06** (2006.01); **A61P 19/02** (2006.01); **A61P 21/04** (2006.01); **A61P 25/00** (2006.01); **A61P 27/02** (2006.01); **A61P 27/16** (2006.01); **A61P 29/00** (2006.01); **A61P 37/02** (2006.01); **A61P 37/06** (2006.01); **C07K 16/00** (2006.01); **C07K 16/24** (2006.01)

CPC (source: EP)

A61P 1/00 (2017.12); **A61P 1/04** (2017.12); **A61P 1/16** (2017.12); **A61P 3/10** (2017.12); **A61P 5/14** (2017.12); **A61P 7/06** (2017.12); **A61P 13/12** (2017.12); **A61P 17/06** (2017.12); **A61P 19/02** (2017.12); **A61P 21/04** (2017.12); **A61P 25/00** (2017.12); **A61P 27/02** (2017.12); **A61P 27/16** (2017.12); **A61P 29/00** (2017.12); **A61P 37/02** (2017.12); **A61P 37/06** (2017.12); **C07K 16/249** (2013.01); **A61K 2039/505** (2013.01); **A61K 2039/545** (2013.01); **C07K 2317/24** (2013.01)

Citation (search report)

- [DX] US 6329511 B1 20011211 - VASQUEZ MAXIMILIANO [US], et al
- [A] EP 0695189 A1 19960207 - GENENTECH INC [US]
- [A] THAKUR A B ET AL: "A POTENT NEUTRALIZING MONOCLONAL ANTIBODY CAN DISCRIMINATE AMONGST IFNGAMMA FROM VARIOUS PRIMATES WITH GREATER SPECIFICITY THAN CAN THE HUMAN IFNGAMMA RECEPTOR COMPLEX", MOLECULAR IMMUNOLOGY, ELMSFORD, NY, US, vol. 36, no. 15/16, 1999, pages 1107 - 1115, XP001159741, ISSN: 0161-5890
- See references of WO 03097082A2

Citation (examination)

- US 2005019323 A1 20050127 - EHRHARDT ROLF [US], et al
- HOMMES ET AL: "Fontolizumab, a humanised anti-interferon gamma antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn's disease.", GUT, vol. 55, 2006, pages 1131 - 1137
- STANGE ET AL: "Therapie der entzündlichen Darmerkrankungen", PRAXIS, vol. 91, 2006, pages 2029 - 2039

Designated contracting state (EPC)

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

DOCDB simple family (publication)

WO 03097082 A2 20031127; **WO 03097082 A3 20041209**; AU 2003231802 A1 20031202; CA 2486147 A1 20031127; EP 1506002 A2 20050216; EP 1506002 A4 20060607; JP 2005529152 A 20050929

DOCDB simple family (application)

US 0315874 W 20030516; AU 2003231802 A 20030516; CA 2486147 A 20030516; EP 03753102 A 20030516; JP 2004505078 A 20030516